Rhumbline Advisers grew its holdings in shares of Emergent Biosolutions Inc (NYSE:EBS) by 0.6% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 146,514 shares of the biopharmaceutical company’s stock after purchasing an additional 905 shares during the quarter. Rhumbline Advisers owned about 0.28% of Emergent Biosolutions worth $8,477,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Ballast Advisors LLC purchased a new stake in Emergent Biosolutions in the first quarter valued at approximately $29,000. Aigen Investment Management LP purchased a new position in shares of Emergent Biosolutions during the fourth quarter worth approximately $32,000. First Quadrant L P CA purchased a new position in shares of Emergent Biosolutions during the first quarter worth approximately $39,000. First Bank & Trust raised its stake in shares of Emergent Biosolutions by 1,105.7% during the fourth quarter. First Bank & Trust now owns 1,049 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 962 shares in the last quarter. Finally, Pearl River Capital LLC purchased a new position in shares of Emergent Biosolutions during the first quarter worth approximately $66,000. Hedge funds and other institutional investors own 85.03% of the company’s stock.

Several research analysts have commented on the stock. Argus lifted their price target on shares of Emergent Biosolutions from $67.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Cantor Fitzgerald raised their target price on shares of Emergent Biosolutions from $75.00 to $86.00 and gave the stock an “overweight” rating in a report on Friday, May 1st. Chardan Capital raised their target price on shares of Emergent Biosolutions from $71.00 to $86.00 and gave the stock a “buy” rating in a report on Friday, May 1st. Cowen assumed coverage on shares of Emergent Biosolutions in a report on Thursday, March 12th. They issued a “hold” rating and a $67.00 target price on the stock. Finally, Wells Fargo & Co raised their target price on shares of Emergent Biosolutions from $75.00 to $85.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $78.71.

In other Emergent Biosolutions news, EVP Adam Havey sold 7,972 shares of the business’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $60.00, for a total value of $478,320.00. Following the completion of the transaction, the executive vice president now owns 37,986 shares of the company’s stock, valued at approximately $2,279,160. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Chairman Fuad El-Hibri sold 13,619 shares of the business’s stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $58.70, for a total value of $799,435.30. Following the completion of the transaction, the chairman now directly owns 1,482,663 shares of the company’s stock, valued at approximately $87,032,318.10. The disclosure for this sale can be found here. In the last three months, insiders sold 222,823 shares of company stock valued at $14,607,361. 14.10% of the stock is owned by insiders.

Shares of Emergent Biosolutions stock opened at $82.49 on Friday. The company has a current ratio of 3.03, a quick ratio of 1.83 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $4.32 billion, a P/E ratio of 63.45 and a beta of 1.25. The business has a fifty day simple moving average of $72.17 and a two-hundred day simple moving average of $60.38. Emergent Biosolutions Inc has a 12 month low of $39.11 and a 12 month high of $90.00.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.01. Emergent Biosolutions had a return on equity of 14.58% and a net margin of 6.15%. The firm had revenue of $192.50 million during the quarter, compared to analyst estimates of $198.79 million. During the same quarter in the previous year, the firm earned ($0.13) EPS. Emergent Biosolutions’s quarterly revenue was up 1.0% compared to the same quarter last year. Analysts predict that Emergent Biosolutions Inc will post 3.13 earnings per share for the current year.

Emergent Biosolutions Profile

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

Further Reading: How To Calculate Debt-to-Equity Ratio

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.